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THE EFFECT OF PROBIOTICS, PREBIOTICS, AND SYNBIOTICS ON INDICATORS OF 
LACTOSE INTOLERANCE: A SYSTEMATIC REVIEW 
 
by 




       Lactose intolerance disproportionately affects racial minority groups in the United States, 
increasing the incidence of calcium deficiency and low bone mineral density in these 
populations. The nutritional quality of lactose-containing food products incentivizes the 
investigation of long-term treatment options for lactose intolerance. Modifying the gut 
microbiome to increase the quantity of lactose-hydrolyzing bacteria in the intestines is a 
promising avenue of treatment that merits investigation. Such modification is typically achieved 
via consumption of probiotics, prebiotics, or synbiotics in various forms. This systematic review 
examined 25 studies measuring outcomes of lactose intolerance in subjects given probiotic, 
prebiotic, or synbiotic treatments. Bacterial strains with the greatest degree of evidence for the 
reduction of undesirable outcomes of lactose intolerance were Bifidobacterium longum, 
Lactobacillus acidophilus, Lactobacillus delbrueckii subspecies bulgaricus, and/or 
Streptococcus thermophilus. Inoculated dairy products also showed strong evidence for the 
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Lactose intolerance is a universal human concern that disproportionately affects several 
minority groups in the United States, adversely impacting the incidence of calcium deficiency 
and low bone mineral density in these populations. The high nutritional quality of many lactose-
containing food products incentivizes the investigation of effective long-term treatment options 
for lactose intolerance. Modifying the gut microbiome to increase the quantity of lactose-
fermenting bacteria in the intestines is a promising avenue of treatment that merits investigation.  
Probiotics and modifications to the gut microbiome have gained support in contemporary 
research due to the specificity, longevity, and associated health benefits of the microbial 
treatment options available. The emerging field of synbiotics investigates the effectiveness of 
pairing probiotic bacteria with supplements that are intended to encourage proliferation of these 
lactose-hydrolyzing bacteria in the intestines. Immense variation is possible in the particular 
probiotic/prebiotic combination, time-course of treatment, strain, colony-forming units (CFUs), 
and method of probiotic encapsulation used in these studies. Emerging evidence suggests that 
probiotics, prebiotics, and synbiotic combinations may be effective at alleviating the symptoms 
of lactose intolerance, but a thorough statistical analysis of available evidence is necessary to 
determine whether these treatments might be effective enough to influence contemporary dietetic 
practices or recommendations.  
Purpose Statement: The purpose of this systematic review is to generate a summative evaluation 
of studies that examine the association between probiotic, prebiotic, and synbiotic treatments and 










Summary and Health Implications: Lactose intolerance is the inability or, more commonly, the 
reduced ability to digest the milk sugar lactose. Ideally, lactose is either hydrolyzed by the 
endogenous lactase enzyme that is produced in the brush border of the small intestine or it is 
digested by bacteria in the gut microbiome that produce similar beta-galactosidase enzymes.1 
When lactose is not hydrolyzed by the consumer nor processed by bacteria in the small intestine, 
common symptoms are flatulence, diarrhea, abdominal pain, cramping, bloating, and nausea.1,2,3 
Interestingly, symptoms unconnected to the digestive tract have also been observed, including 
eczema, fatigue, headaches, sinusitis, and cardiac arrhythmia.1 
These symptoms are understandably upsetting for the consumer, and they can promote 
avoidance of lactose-containing products. This moratorium can be difficult to maintain given the 
ubiquity and popularity of milk-based beverages, coffee creamers, chocolates, cheeses, butter, 
ice cream, and even lactose-based sweeteners used in food manufacturing. Successful avoidance 
of such products by lactose-intolerant individuals is associated with increased rates of 
osteoporosis, osteopenia, and low bone mineral density.2,3 These effects are ostensibly due to 
insufficient calcium consumption. This illustrates the connection between lactose intolerance and 
critical measures of human health. 
History and Demographics: Lactase enzyme production into adulthood, also called lactase 
persistence, is an evolutionarily new development. Soon after agrarian and pastoral Neolithic 
societies began to flourish in Europe between 8500 and 6000 years ago, a beneficial mutation 





in Northern Europeans.4 This genetic bias toward lactase persistence in adulthood still exists 
today, as evidenced by lactose intolerance prevalence that is comparatively low (14-28%) among 
central and western Europeans and extremely high in Asian Americans (approximately 80-90%), 
African-Americans (75-90%), and indigenous Americans (nearly 100%).3,5 Regional prevalence 
of lactase persistence is another consideration, as some endogamous or otherwise genetically 
homogenous populations can have very consistent and extreme rates of lactase persistence. In 
2005, Paul Sherman and his research team5 discovered a 2% prevalence of lactose intolerance in 
a sample of Denmark citizens and a 100% prevalence of lactose intolerance in a sample taken 
from Zambia. Providing an effective means of promoting lactose digestion in populations 
lacking lactase persistence may increase dairy product consumption, attenuate calcium 
deficiency, and improve bone mineral density. This is especially critical for traditionally 
marginalized populations who, in addition to having greater prevalence of lactose intolerance, 
also may have reduced access to affordable healthcare or may lack health insurance entirely.6  
Available Treatments: The most common treatment for lactose intolerance that does not require 
dietary restriction is ingestion of exogenous lactase enzyme. Lactase enzyme products contain 
beta-galactosidases in concentrations that will vary between manufacturers but tend to have 
between 3000 and 6000 IU of active lactase enzyme. These pills, capsules, or tablets are intended 
to be consumed immediately before a meal and are regarded as effective at hydrolyzing 
consumed lactose.7 In key studies of the effectiveness of exogenous lactase enzyme 
consumption, both gastrointestinal distress symptoms and breath hydrogen values were 
significantly reduced in treatment groups of various ages following a 25g lactose bolus.7,8 
Similar commercial lactase products, whether in pill, capsule, or chewable form, were not as 





consume such a high dose of lactose in one sitting. Limitations of lactase enzyme consumption 
include the narrow timeframe in which the product will function6,7 and the requirement that the 
lactase be consumed before every lactose-containing meal. Attenuating lactose intolerance via 
adjustments to the gut microbiome is another potentially viable treatment option. While much is 
known about the requisite microbiology, contemporary studies attempting to investigate this 
avenue of treatment tend to have mixed results, and no robust meta-analyses of contemporary 
data have been performed. Consequently, there is not yet sufficient evidence as to whether a 
specific probiotic, prebiotic, or synbiotic (see Table 1) treatment is effective in reducing lactose 
intolerance symptoms.  
 
Table 1. Glossary of Terms 
Probiotics Live microorganisms that, when administered in adequate amounts, confer a 
health benefit on the host9 
Prebiotic A substrate that is selectively utilized by host microorganisms conferring a 
health benefit9 
Synbiotics A mixture comprising live microorganisms and substrate(s) selectively 
utilized by host microorganisms that confers a health benefit on the host10 
Microbiome A characteristic microbial community occupying a reasonable well-defined 
habitat which has distinct physio-chemical properties. This community is 
integrated in macro-ecosystems including eukaryotic hosts, and it can be 
crucial for the host’s functioning and health11 
Microbiota The assemblage of living microorganisms present in a defined environment11 
 
Dysbiosis An imbalance in the composition and functional capacity of the host 
microbiota12 
Metagenome The collection of genomes and genes from the members of (in this context) 
the host microbiota13 
 
The Gut Microbiome as a Target of Lactose Intolerance Intervention 
Measuring Alterations in the Gut Microbiome: Experimentally researching the gut microbiome 





and human health, pure axenic cultures of the bacteria must be made, their effects on a host must 
be observed, and their biological roles in the human body must be ascertained from this isolated 
data. These data are still limited in their external validity because each bacterium lives amid 
millions of immediate bacterial neighbors in the small intestine, and each study participant’s gut 
microbiome composition will be different. The metabolism of any given bacterium will also vary 
based on the host’s nutrition, stool consistency, drug treatments, hydration status, stress level, 
and other factors.14  
 The goal of a probiotic and/or prebiotic intervention, then, is to promote a change in the 
gut microbiome of a sufficient magnitude to result in an observable change in the host via stool 
samples, breath composition tests, lactose tolerance tests, or perceived symptoms of 
gastrointestinal distress over time.14,15 Methods to quantify and describe gut microbiome 
composition via stool samples or biopsied small intestine samples include metagenomics and the 
complementary approach of culturomics.16  Metagenomics is the practice or field of study 
concerned with the analysis and categorization of a microbial metagenome via extraction of 
nucleic acids from microbial samples, either via shotgun sequencing of the whole DNA sample 
or via polymerase chain reaction and subsequent 16s rRNA sequencing.16,17,18 The results are 
then compared to an expanding database of 16s rRNA gene sequences and more broad genomic 
profiles intended for shotgun sequencing such as those catalogued by NCBI’s Gene Expression 
Omnibus (GEO),19 GenBank,20 and the Genomics OnLine Database (GOLD).21 There is some 
contention as to the terminology used in this field; some researchers consider 16s rRNA to be a 
type of targeted metagenomics and shotgun sequencing to be shotgun metagenomics,17 while 
others do not consider 16s rRNA sequencing to be an application of metagenomics at all.18 In 





information about probiotic treatment outcomes, at least in terms of colonization. There are 
drawbacks to this approach, however. A sufficient quantity of high-quality nucleic acid samples 
are required for metagenomic analysis, and the quality of samples may vary between extraction 
methods.17,18 There is also some difficulty achieving sufficient sequence coverage for minority 
bacterial populations, so metagenomic analyses are not always sensitive enough to detect 
bacteria that are present in small quantities due to this “depth bias”.17,22 Sorting genes of interest 
into orthologous groups during a metagenomic analysis can help researchers avoid some of these 
issues and glean useful data about the subject’s gut microbiome composition, as demonstrated in 
2011 by M. Arumugam et al.23 Still, depth bias presents identification issues, as does the amount 
of “microbial dark matter”, or unassigned gene sequences, yet to be described and identified by 
metagenomics.16 This highlights the benefit of performing a mixed-methods analysis of fecal 
samples. Such mixed-methods analyses may include elements of both metagenomics and 
culturomics.  
 Culturomics is the field of study concerned with culturing microorganisms from a 
bacterial or fungal sample in order to collect data about the physical, chemical, and metabolic 
properties of an organism or of the organisms in a microbiome. Methods of bacterial 
identification and description intrinsic to culturomics include liquid and solid culture media, 
gram staining, fluorescent molecule staining, electron microscopy, carbohydrate utilization tests, 
enzyme function tests, and matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS).16,17,22,24 MALDI-TOF MS is a method of bacterial 
identification valued for its speed and cost-effectiveness15 and it is sometimes preferred over 
identification via 16S rRNA sequencing.25 Through culturomics, researchers have been able to 





and gradually refine and optimize ideal culture conditions for the growth of previously 
uncultured species.16,22,26 
 The efficacy of the synthesis of metagenomics and culturomics has been demonstrated in 
a study of dysbiosis in Clostridium difficile infection in which the researchers cultured 112 new 
bacterial species27 and observed little overlap between species detected by metagenomics and 
those detected by culturomics. A study examining fungal populations in the human gut 
mycobiome (fungal microbiome) observed the same small overlap between species detected by 
metagenomic methods as compared to culturomics,28 reinforcing the notion that a mixed-
methods approach provides more detail about the gut microbiome. Studies investigating the 
effect of probiotics and prebiotics may obtain broader outcome data by examining subjects’ stool 
samples before and after treatment using both metagenomics and culturomics-based approaches. 
Researchers may also benefit from utilizing these approaches with samples taken from the small 
intestine, where lactase production and carbohydrate hydrolysis ordinarily take place. In this 
review, the methodology by which researchers analyze and describe the outcomes of probiotic 
and prebiotic treatment will be considered, with an emphasis on conclusions derived from 
mixed-methods analyses. 
Hydrogen breath tests, lactose tolerance tests, and subjective measures of gastrointestinal 
symptoms of maldigestion are more consistent measuring tools for bacterial activity than stool 
samples; measurements can be taken repeatedly over a span of multiple hours and can be used to 
ascertain both baseline and endpoint values.29 These outcome variables, in contrast to 
metagenomic and culturomic data, are frequently available in the existing literature and were 






Mechanisms of Action of Probiotic Bacteria 
Overview: The wide genotypic and phenotypic diversity of the human gut microbiome gives 
probiotics manufacturers a rich bevy of candidate species to choose from when developing 
products, and each species or combination of species may have different avenues through which 
they improve human health. The exact number of species present in the gut microbiome is 
unknown and is the subject of contemporary research. In early 2019, a research team from the 
Wellcome Genome Campus and Centre for Innate Immunity and Infectious Diseases identified 
2,505 total intestinal microbial species, including 1,952 uncultured species, using shotgun 
sequencing and nucleotide frequency analysis data from 75 different studies to construct 
metagenome-assembled genomes (MAGs).30 While this gives some idea of the breadth of 
species in the gut microbiome, it might be more practical to look at species that are shared 
within-groups to identify a core representative human gut microbiome composition. In the fall of 
2019, a research team based out of George Washington University published an analysis of 98 
fecal samples from healthy subjects, identifying 155 different bacterial organisms and a 
contingent of 84 species that were present in all samples.31 The majority (79.7%) of the 155 
species identified belonged to the phyla Firmicutes, Actinobacteria, and Bacteroidetes. This 
finding is consistent with the taxa of common probiotic candidates, including various species of 
the genus Bifidobacterium from the phylum Actinobacteria and various species of the recently-
reclassified clade of Lactobacillus from the phylum Firmicutes.32,33 The diversity of probiotic 
species is reflective of the variety of benefits that these probiotics are intended to have for their 
hosts. Benefits of probiotics that pertain to attenuation of lactose intolerance outcomes include 
competitive exclusion of potentially pathogenic bacteria, immune modulation, and the 





Competitive Exclusion and Growth Inhibition of Pathogenic Bacteria: Organisms of different 
species that occupy the same ecological niche tend to compete for the limited resources within 
that niche, and gut microbes are no exception. Through hydrophobic interactions with the host’s 
intestinal lining, acidification of the luminal environment, and the production of specialized 
proteins, probiotic bacteria are able to adhere to the gastrointestinal tract and prevent the 
adhesion of pathogenic bacteria.35 In this way, probiotic bacteria have been shown to inhibit the 
intestinal cell adhesion and colonization of Salmonella typhimurium, Clostridium sporogenes, 
and Enterococcus faecalis.36 Lactobacillus and Bifidobacterium species are particularly good 
candidates for promoting competitive exclusion due to the mucin-binding proteins and 
fibronectin-binding proteins that are characteristic of these species, a prime example of which is 
Lactobacillus rhamnosus, which has a mucin-binding protein on the tips of its pili.37 Recently, it 
has also been proposed that probiotic bacteria may interfere with a type of communication called 
quorum sensing among pathogenic bacteria by inhibiting and degrading signaling molecules in 
the human gastrointestinal tract.38 This mechanism of pathogenic inhibition has shown efficacy 
in reducing the population of pathogenic Aeromonas hydrophila in the intestines of goldfish.39 
 Aside from adhering to the intestinal wall and facilitating the interruption of quorum 
sensing, some probiotic bacteria also practice competitive exclusion by producing antimicrobial 
proteins called bacteriocins.34,36 A prime example is the production of plantaricin by 
Lactobacillus plantarum; plantaricin is deadly to many bacteria associated with foodborne 
illness, including multiple species of the genera Staphylococcus and Listeria.40 Similarly, 
Lactococcus lactis produces the bacteriocin nisin, which has been shown to be antagonistic to the 
gram-positive bacteria Bacillus cereus and Staphylococcus aureus, as well as the gram-negative 





bacteria are typically resistant to the effects of bacteriocins.42 Probiotic bacteria have a wide 
variety of avenues through which they might practice competitive exclusion. Contemporary 
research of these antimicrobial and anti-pathogenic properties of probiotics make them a 
promising treatment candidate for lactose intolerance, as they may confer some benefit against 
foodborne illness in addition to improving the digestibility of lactose-containing products. 
Immune Modulation: In addition to the competitive exclusion of potentially pathogenic bacteria, 
some probiotic bacteria have been shown to affect the host’s immune system. The same 
mechanism of adhesion to intestinal epithelial cells described above allows probiotic bacteria to 
remain adjacent to the glycocalyces of intestinal epithelial cells, where microbial metabolites, 
signaling proteins, and cell-surface molecular patterns exert an influence on specialized pattern 
recognition receptors (PRRs), including toll-like receptors.43 Responses of the intestinal 
epithelium and the immune cells of the lamina propria include the reinforcement of tight 
junctions, the stimulation of dendritic cells, and the production of interleukins and 
cyclooxygenases. This innate immune response has been shown to prime adaptive immune 
responses by modulating CD4 T-cell generation and activity.44 For example, a dose of 5E9 CFUs 
of Lactobacillus casei fed to Lewis rats 3 times per weeks for several months resulted in a 
statistically significant reduction in CD4+ T-cells responsible for producing tumor necrosis factor 
alpha (TNF-α) and a statistically significant increase in CD4+ T-cells responsible for producing 
the anti-inflammatory cytokine interleukin-10.45 The rats in this treatment group experienced 
significantly fewer clinical signs of collagen-induced arthritis, including paw swelling, which 
indicates a systemic effect on inflammatory response that was not localized to the intestines.  
 A later study investigated the effect of a combined probiotic containing Bifidobacterium 





thermophilus on intestinal inflammation in BALB/c mice. Numerous in vivo and ex vivo 
experiments were performed, and the research team discovered that administration of 5E8 
CFUs/day of the combined probiotic over 20 days induced CD11c+ regulatory dendritic cells, 
which generated CD4+Fox3+ regulatory T-cells that had an anti-inflammatory effect on the 
intestinal cells of mice with inflammatory bowel disease.46 This research is promising in that it 
shows a pronounced effect on immune and inflammatory responses from a relatively short 
course of probiotic treatment, and it reinforces the fact that probiotics have varied and diverse 
effects on the gastrointestinal tract.  
 The wide variety of these effects necessitates caution when interpreting the results of 
lactose intolerance interventions. In 2009, an exceptionally thorough systematic review revealed 
that probiotics can have an effect on lactose intolerance symptoms such as diarrhea and colitis in 
either the presence or absence of lactose intolerance.47 In short, some probiotics which are 
hypothesized to alleviate lactose intolerance symptoms may do so through mechanisms that have 
little, if anything, to do with improving carbohydrate digestion. This may help to explain why 
some probiotic treatments result in a reduction in lactose intolerance symptoms with no 
significant changes in hydrogen breath test values.29 
Lactase Enzyme Production: Improving carbohydrate digestion is typically the primary aim of 
lactose intolerance interventions, unless the chosen intervention is the avoidance of lactose-
containing foods. In addition to competitive exclusion of potentially pathogenic bacteria and the 
modulation of the host’s immune system, many probiotic bacteria that are intended to alleviate 
lactose intolerance symptoms are selected because they produce beta-galactosidase, or lactase 
enzyme, which hydrolyzes lactose into glucose and galactose. This sounds like a straightforward 





to the colon by undigested lactose, but this mechanism is complicated by the observation that 
gases produced by colonic bacteria from fermented carbohydrates also contribute to lactose 
intolerance symptoms such as bloating, flatulence, and borborygmi.48 Also, a 28-subject study 
conducted in 2005 investigated the microbial compositions of subjects’ fecal samples and 
discovered that there was no significant difference in the prevalence of beta-galactosidase 
producing bacteria in the samples of lactose-intolerant subjects as compared to lactose-tolerant 
subjects.49 Interestingly, there was also no correlation between the prevalence of beta-
galactosidase producing bacteria and beta-galactosidase activity. Again, this hints at the 
complexity of the interplay between probiotic bacteria and lactose intolerance outcomes; simply 
providing the host with probiotic bacteria that can produce lactase enzyme may not reliably and 
significantly alleviate lactose intolerance symptoms. 
  Still, lactase production is a desirable quality in probiotic species intended for lactose 
intolerant individuals. Lactase producing bacteria that are generally recognized as safe include 
Bacillus licheniformis, Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus 
acidophilus, Lactobacillus delbrueckii subspecies bulgaricus, Lactobacillus helveticus, 
Lactobacillus reuteri, Streptococcus thermophilus, and many others.50,51,52 Some molds such as 
Aspergillus phoenicis have also been shown to produce lactase enzyme,53 but they are typically 
just used for the production of commercially available exogenous lactase products and are less 
common as probiotic candidates. Normally, the host’s endogenous lactase production occurs in 
the jejunum and, to a lesser extent, the ileum, and this is where the hydrolysis of lactose and 
absorption of the resultant glucose and galactose occur.54 Though bacteria populate the colon 
significantly more densely than the small intestine, the ideal site of colonization for a probiotic 





carbohydrates the reach the colon and the gaseous products produced by colonic bacteria 
contribute to lactose intolerance symptoms.48 In order to assess whether the effect of a probiotic 
or prebiotic intervention on lactose intolerance outcomes was due to lactase enzyme activity, the 
lactose tolerance test is preferred to the hydrogen breath test,56 as the lactose tolerance test 
measures a change in blood glucose in response to a bolus of lactase. An increase in exogenous 
lactase production by probiotic bacteria in the small intestine may allow the host to absorb the 
products of lactose hydrolysis and thus will impact blood glucose. This is preferable to the 
fermentation of carbohydrates in the colon, which does not allow the host to absorb glucose or 
galactose.  
Mechanisms of Action of Prebiotics and Synbiotics 
 As a reminder, prebiotics are substrates that are selectively utilized by the host’s 
microbiota to confer a health benefit upon the host,9 while synbiotics are combinations of 
probiotic and prebiotic treatments that confer a health benefit upon the host.10 Prebiotics are 
intended to be digested by gut bacteria, so common candidates for research are polysaccharides 
and oligosaccharides that humans cannot digest such as inulin,57 fructo-oligosaccharides, 
galacto-oligosaccharides, trans-galacto-oligosaccharides,58 raffinose, stachyose,59 and fucosyl-
oligosaccharides.60 The host’s gut microbiome composition changes in response to the diet, but 
prebiotics allow the host to make deliberate and targeted modifications. When the 
gastrointestinal tract is consistently exposed to the same carbohydrate sources, bacteria that favor 
these carbohydrate sources tend to flourish in a process that is, in this context, called 
adaptation.61,62 Adaptation of the gut microbiome in response to prebiotics may then exert the 
same mechanisms of action (competitive exclusion, immune response modulation, and enzyme 





 Of particular interest is the administration of specific formulations and doses of prebiotics 
to elicit a reliable change in the prevalence of particular species of bacteria, but adaptations in 
the gut microbiome are reported more broadly as genus-wide changes. This is especially evident 
in the “bifidogenic effect” of fructo-oligosaccharides, and galacto-oligosaccharides.63 As early as 
1990, it was shown that consuming 10g of raffinose and stachyose daily for 3 weeks increased 
participants’ fecal concentrations of bifidobacteria, but no specific species were evaluated in 
vitro.64 In vivo, however, this same raffinose and stachyose prebiotic was shown to be fermented 
as effectively as glucose by Bifidobacterium longum, Bifidobacterium breve, and 
Bifidobacterium infantis, but less effectively by Bifidobacterium bifidum. Pathogenic bacteria 
including Clostridium perfringens, Escherichia coli, and Clostridium difficile did not ferment the 
prebiotic, indicating the benefit of selective substrate utilization in microbial dynamics such as 
competitive exclusion.64 More recently, a research team from the Department of Microbiology 
and Immunology in Leuven, Belgium, observed a modest increase in populations of 
Bifidobacterium and Anaerostipes species in the gastrointestinal tracts of subject who were fed 
inulin.65 It may be the case that species-level adaptations are much more easily achieved via 
probiotic use, whereas prebiotics tend to have a significantly less targeted effect.  
 Synbiotics seek to combine probiotic bacteria and the prebiotics that are best-suited to 
those bacteria. There is some evidence that inulin and/or fructo-oligosaccharides may help 
support probiotic species such as Lactobacillus paracasei and Bifidobacterium bifidum,66 but few 
studies examine alterations of the gut microbiome in response to synbiotic treatment. An in vitro 
study conducted in 2016 investigated the fermentative capacity of five Lactobacillus species and 
2 Lactococcus species and discovered that, of the xylo-oligosaccharides, xylobiose was 





may not generalize well to the complicated bacterial milieu of the gut microbiome, analyzing the 
effectiveness with which probiotic bacteria ferment particular oligosaccharides may give some 
insight as to which prebiotics will pair best with which probiotics. Ostensibly, this synergy may 
improve probiotic colonization and the capacity for competitive exclusion of pathogens.  
Contemporary Research 
 Recent systematic reviews of the topic have either revealed inconclusive68 or overall 
positive69,70,71 results, but these investigations tended to be limited by their heterogeneity of 
outcome variables, small quantity of included studies, small sample sizes of included studies, 
methodological heterogeneity, and lack robust statistical models examining the available data.  
 A 2005 systematic review examining the effect of probiotic supplementation on 
participants’ hydrogen breath test values or lactose intolerance symptom scores reported 
inconclusive results.68 The researchers searched AMED and Medline databases for relevant 
studies, and they called and emailed researchers and Lactobacillus probiotic manufacturers to 
locate additional studies. A lack of standardized data prevented a pooled statistical analysis of 
the 10 included studies, and the small sample sizes of the studies (from 5 to 20 participants) may 
have promoted an increased incidence of type II errors among the study results. Of the 9 studies 
measuring hydrogen breath test values, an equal number reported positive, negative, and mixed 
outcomes. Of the 7 studies measuring symptom outcomes, one returned positive results, five 
returned negative results, and one returned mixed results.68 The researchers concluded that strain, 
concentration, and duration of wash-out period might affect the measured outcomes. A robust 
statistical analysis should ideally stratify the data by these variables to examine their effect on 





 The 2012 textbook Probiotics contains a chapter specifically addressing the use of 
probiotics to alleviate lactose intolerance symptoms. This chapter describes bacterial species 
known to increase β-galactosidase activity in the feces, including Bifidobacterium breve, 
Bifidobacterium longum, and Lactobacillus casei.69 Antibiotics are included as a potential 
confounding factor in the effectiveness of probiotic treatments, which indicates that recent and 
ongoing antibiotic use would be a sensible exclusion criterion for probiotic trials. The authors 
concluded that probiotics provide a promising avenue of treatment for lactose intolerance 
symptoms, and there is evidence that some strains of bacteria are effective, but further research is 
needed.  
 A 2018 systematic review examined studies that investigated the effects of probiotic 
supplementation on a variety of outcomes, particularly outcomes pertaining to symptoms of 
lactose intolerance. Databases and catalogues used included PubMed, Google Scholar, Ovid 
MEDLINE, Web of Science, Food Science and Technology Abstracts, Cochrane Central 
Register of Controlled Trials, Current Contents Connect, and Clinicaltrials.gov.70 Of the 94 
unique full-text clinical trials assessed, 15 were included in the review, and a total of 8 bacterial 
species were investigated in the selected studies. The researchers reported mixed results but an 
overall positive trend of reduction in the incidence and severity of lactose intolerance symptoms, 
though these results varied between species. Bacteria displaying moderately strong evidence for 
relief of one or more lactose intolerance symptoms included Bifidobacterium longum, 
Bifidobacterium animalis, and Lactobacillus rhamnosus, with the caveat that consumption of 
Lactobacillus rhamnosus probiotics may have adverse side effects for populations with poor 
immune function.70 By contrast, the researchers concluded that there is insufficient evidence to 





Lactobacillus acidophilus, Saccharomyces boulardii, and Streptococcus thermophilus to 
alleviate lactose intolerance symptoms.70 In the case of Lactobacillus reuteri, the two clinical 
trials that were examined yielded positive results, but more studies are necessary to provided 
definitive evidence of its effectiveness. Many of these studies were limited in sample size and 
duration, and no statistical analysis was performed. Similar to previous systematic reviews, this 
research highlights the need for a robust statistical analysis that pools available data and stratifies 
outcome variables by bacterial species to offer a clearer measure of the effectiveness of a given 
probiotic treatment.  
 More recently, a systematic review published in 2020 examined 9 studies investigating 
the effects of prebiotic and/or probiotic supplementation on a reduction in lactose intolerance 
indicators and found an overall positive trend. The researchers drew the studies from PubMed 
and SCOPUS databases, then they manually searched the bibliographies of these studies for 
additional resources.71 Statistically significant reductions in hydrogen breath test values and/or 
lactose intolerance symptom scores were reported in studies of probiotics that contained 
Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus reuteri, Lactobacillus 
rhamnosus, Bifidobacterium longum, and Streptococcus thermophilus, while the study 
examining the effect of Lactobacillus plantarum and Bifidobacterium animalis did not show 
significant results.71 Of the 9 studies included, only two were discussed in the aforementioned 
2018 systematic review, and the findings concerning the effectiveness of L. acidophilus, B. 
animalis, and L. reuteri differed between the two reviews.70,71 This may be due to the differences 
in database search methodologies and outcome variables measured in these reviews, and it 







Protocol and Registration 
This systematic review was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) checklist,72 and the study rationale and 
methodology were prospectively submitted to PROSPERO. 
Inclusion Criteria 
A study was eligible for inclusion in the systematic review if it met the following criteria: 
(1) Human participants in a treatment group received probiotic and/or prebiotic supplementation 
of a specified dosage. Genus and species of the probiotic(s) and/or chemical name(s) of the 
prebiotic(s) were identified.  (2) Human participants in a control group received a placebo that 
was unlikely to substantially affect gut microbiome composition or participants’ pre-test and 
post-test results were evaluated. (3) The outcomes of interest included any indicator of lactose 
maldigestion or lactose intolerance. (4) The study excluded participants with gastrointestinal 
diseases, cancer/chemotherapy, antibiotics, milk protein allergy, and/or those who were taking 
medications that may affect gastrointestinal motility or microbiome. One exception to this 
criterion is IBS with concomitant lactose intolerance, as this is a clinically relevant subgroup of 
lactose intolerant individuals and does not preclude their participation in lactose intolerance 
research. (5) The study was peer-reviewed, and its full text was accessible.  
Literature Search 
Search databases included SCOPUS, MEDLINE, WORLDCAT, EMBASE, Web of 
Science, Cochrane Library, NIH-HMP studies, and Central Washington University’s OneSearch. 
The initial search string used was (Probiotic* OR prebiotic* OR synbiotic* OR “beneficial 





AND (“Lactose intolerance symptoms” OR bloating OR gas OR flatulence OR diarrhea OR 
“gastric distress” OR indigestion) NOT (rat* OR mice OR mouse). An additional search was 
performed using the terms Lactobacillus, Bifidobacterium, probiotic*, prebiotic*, synbiotic*, 
“lactose intolerance”, Saccharomyces boulardii, and Streptococcus thermophilus. 
Review papers and reference lists were also examined for suitable studies. Searches were not 
limited by language. Studies written in non-English languages were translated to English via the 
Linguee database, and any unclear translations were cross-referenced with SDL Trados Studio 
translation software.  
Study Selection 
Eligible studies were sorted to eliminate duplicates, then the titles and abstracts of the 
eligible studies were examined to determine whether they fulfilled all of the above inclusion 
criteria. In the event of ambiguity or significant threats to internal validity, suitability for a 
study’s inclusion in the review was determined by committee to minimize selection bias. 
Selected studies were read in full and further evaluated for inclusion, again based on the above 
criteria. 
Quality Assessment and Data Gathering 
Data gathering was conducted according to the Cochrane training manual73 methodology. 
A study quality and risk of bias assessment was performed according to the Cochrane Revised 
Tool to Evaluate Risk of Bias in Randomized Trails,74 also known as the RoB 2, while cohort 
and case-control trials were to be assessed via the 9-point Newcastle-Ottawa Scale.75 
Statistical Analysis 
Due to significant methodological heterogeneity in the included studies, statistical 





used for all stages of statistical analysis. Potential publication bias was to be assessed via Begg’s 
funnel plots, and Egger’s linear regression test was to be used to evaluate heterogeneity. 
Additional assessments of heterogeneity would include an I2 calculation and the Q statistic at a 
level of significance of P < 0.10. A pooled Chi-square analysis was to be performed on the 
lactose intolerance symptom score data, and a comparison of pooled means was to be used to 
evaluate the hydrogen breath test data, adjusted for age, sex, and dietary intake. A random-







 The search string yielded a total of 1,411 search results comprised of 1,046 items from 
Central Washington University’s OneSearch database, 75 from PubMed, 257 from WorldCat, 33 
from Cochrane Library, and 0 from the NIH Human Microbiome Project. Of these items, 135 
duplicates were eliminated. When duplicates were eliminated, only the most recently-updated 
item was retained so that revised papers would be preferentially spared. In an abstract review of 
the remaining 1,276 results, 978 were eliminated for not matching the relevant study parameters, 
including 922 studies investigating unrelated topics and 56 studies without interventions or 
treatments. The studies investigating unrelated topics primarily featured investigations of other 
GI disorders causing similar symptoms, so when this systematic review is updated or replicated 
it may be useful to update the search string to dis-include terms such as “irritable bowel 
syndrome”, “Clostridium difficile infection”, “radiotherapy”, “chemotherapy”, and “small 
intestinal bacterial overgrowth”. Of the remaining results, 275 were somewhat relevant and were 
considered for citation mining and for potential inclusion in a review of relevant literature, and 
23 were read in full and considered for inclusion in the review after an evaluation of their 
methodologies (see Figure 1). Citation mining uncovered 2 additional studies, so 25 studies were 






Figure 1: Flow diagram of study selection process including records identification, eligibility assessment, citation 
mining, and total number of studies included (n = 25) 
 
Cochrane Risk-of-Bias Assessment 
The RoB 2 is a risk-of-bias assessment tool that evaluates studies for their degree of bias along 
the domains of selection, adherence, outcomes, measurements, and reporting. Possible 
evaluations for each domain are either “low risk of bias,” “some concerns,” or “high risk of 
bias.”74 Of the 25 studies included in the systematic review, 9 featured some concerns in the 
selection domain, primarily due to unspecified or nebulous methodology regarding recruitment 
of subjects.78,81,84,86,88,89,91,92,96 The adherence domain evaluates both adherence to study protocols 
and blinding. Only 5 studies showed some concerns due to a lack of blinding,76,82,84,90,95 while 
one study showed high risk of bias in this domain due to a failed attempt at blinding, wherein the 





featured unclear methodology regarding dissemination of outcome data,76,78,91 but risk of bias 
was assessed as low. In the measurement domain, one study showed high risk of bias due to a 
likely carryover effect,88 while another study showed a carryover effect but adjusted for it.92 
Other causes for concern were the use of a 50g lactose bolus82 and the allowance of caffeine 
during testing.84 All but one study showed low risk of bias in the reporting domain. This study 
relied on unpublished research to evaluate the effect of a probiotic treatment,78 so risk of bias 
was considered high for this domain. For any study and domain not referenced above, risk of 








The treatments utilized for each study and the primary study results and conclusions are 
described in Table 2 below, then this is followed by a narrative synthesis and systematic review 
of the included studies. 
 
Table 2. Key Characteristics and Conclusions of Probiotic Studies 
Research Team Year Sample Treatment(s) Findings 
Almeida et al 2012 27 2E7-2E9 CFUs 
L. casei Shirota 




3x/d for 4 
weeks 
*Total lactose intolerance symptom 
scores were reduced in the treatment 
group compared to baseline (p < .01). 
*Total breath hydrogen scores were 
reduced in the treatment group compared 
to baseline (p = .04). 
*Total symptom scores and breath 
hydrogen scores were still significantly 
reduced upon 3-month follow-up (p < .05) 
Cano-Contreras et 
al 









daily for 8 
weeks 
*Total lactose intolerance symptom 
scores were reduced in the treatment 
group compared to baseline (p < .001). 
*46.4% of subjects in treatment group and 
0% of subjects in placebo group achieved 
50% or greater reduction in total 
symptoms relative to baseline. 





daily for 6 
months 
*Significant reductions in symptom 
frequency (p <.05) for bloating, 
flatulence, abdominal discomfort, and 
constipation, but not diarrhea.  
*Breath hydrogen scores trended toward a 







Table 2 (Continued)     
Research Team Year Sample Treatment(s) Findings 




and appx 1E8 
CFUs B. 
animalis per 
gram 3x/d, as 
well as 2E8 
CFUs B. 
longum in 
capsule 3x/d for 
2 weeks 
*Beta-galactosidase activity in feces was 
significantly increased after treatment (p < 
.01), but not after 8-day follow-up. 
*Total symptom scores were significantly 
lower upon follow-up than at baseline (p 
< .02). 
Kim et al 1983 24 5mL/kg body 
weight of whole 
milk containing 
either 0, 2.5E6, 
2.5E7, or 2.5E8 
CFUs/mL of L. 
acidophilus 
daily for one 
week 
*Significant reductions in breath 
hydrogen were observed in the 2.5E6 
CFUs/mL (p < .025) and 2.5E8 CFUs/mL 
(p < .01) groups, but not the 2.5E7 
CFUs/mL (p > .35) group.  












100 CFUs/g of 
the same daily 
for 15 days 
*Significant reductions in total GI 
symptoms were observed for lactose 
malabsorbers consuming non-pasteurized 
yogurt as compared to pasteurized yogurt 
(p = .037).  
*No significant differences in fecal 
weight nor frequency. 
*Overall shorter orocecal transit time for 
pasteurized yogurt (10.5 hr ± .6) 






Table 2 (Continued)     
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each at 1E8 and 
1E9 CFUs/mL 




*Both L. bulgaricus-containing milks 
resulted in significant reductions in 
hydrogen breath values (p < .05) and 
symptom scores (p < .05) compared to 
control milk.  
*L. acidophilus milk containing 1E9 
CFUs/mL resulted in significant reduction 
in symptoms scores (p < .05) but no 
significant reduction in hydrogen breath 
values. 





CFUs L. lactis 
and 1E10 CFUs 
S. thermophilus 
*Both L. acidophilus and L. lactis/S. 
thermophilus milks resulted in 
significantly lower mean symptom scores 
(p < .001 and p < .05, respectively) than 
un-inoculated milk.  
*Significantly lower breath hydrogen 
scores were seen with L. lactis/S. 
thermophilus milk (p < .001). 
Mummah et al 2014 16 Raw milk, 
pasteurized 
milk, or soy 
milk, each 
consumed in 
doses of 16oz 
days 1 and 8. 
Consumption 
was 4oz on day 
2, increasing by 
4oz/d to 24oz 
on day 7. 
*No significant difference observed 
between raw and pasteurized milk in 
terms of symptom scores. 
*Day 1 peak and AUC breath hydrogen 
scores were significantly higher for 
subjects consuming raw milk than for 
pasteurized milk (p = .01).  
*Day 8 AUC breath hydrogen for subjects 
consuming raw milk were significantly 
lower than day 1 scores (p = .05), 
indicating potential microbial adaptation. 
Ojetti et al 2010 60 9,000 standard 




test (HBT) or 
4E8 CFUs L. 
reuteri pill 2x/d 
for 10 days 
*Significant reduction in hydrogen breath 
test scores was recorded for both L. 
reuteri (p < .01) and tilactase (p < .001) 
compared to placebo. 
*Significant reduction in clinical 
symptom scores was observed for both L. 






Table 2 (Continued)     
Research Team Year Sample Treatment(s) Findings 
Pakdaman et al 2016 38 1E10 CFUs L. 
acidophilus 
DDS-1 daily for 
4 weeks 
*Significant reductions in overall 
symptom scores were observed in the 
treatment group (p = .037) as compared to 
the control. Specifically, there were 
reductions in abdominal cramping (p = 
.012), diarrhea (p = .033), and vomiting (p 
= .002). 







daily for 2 
weeks or Dialac 
(“Heat-killed 
probiotic”) 
*Both live and killed L. rhamnosus and L. 
helveticus probiotic treatment resulted in 
significantly lower hydrogen breath test 
scores (p < .001). 
* Hydrogen breath test scores of subjects 
taking live probiotics were not 
significantly different from those taking 
heat-killed probiotics (p = .453). 
*At baseline, 13.9% of subjects were 
asymptomatic. After treatment with either 
probiotic 58.2% of subjects were 
asymptomatic, but no statistical 
significance was calculated or reported. 
Rizkalla et al 2000 24 500g/d fresh 
yogurt 
containing > 







100 CFUs/g of 
the same daily 
for 15 days 
*Breath hydrogen AUC was significantly 
reduced after both fresh and heated yogurt 
consumption (p < .001 for both) as 
compared to baseline.  
*Fresh yogurt had a treatment effect on 
baseline HBT values that carried beyond 
the washout period, indicating potential 
adaptation of the gut microbiome.  
*Significantly greater increases in plasma 
butyrate concentrations were observed for 
fresh yogurt as compared to pasteurized 





Table 2 (Continued)     
Research Team Year Sample Treatment(s) Findings 
Roškar et al 2017 44 5E9 CFUs L. 
plantarum 
MP2026 and 
5E9 CFUs B. 
animalis IM386 
daily for 6 
weeks 
*Significant reductions in the incidence of 
diarrhea (p < .05) and severity of 
flatulence were observed for the treatment 
group. 
*Significant reductions in abdominal pain 
(p < .01), flatulence (p < .01), and 
boborygmi (p < .05) were observed for 
the placebo group. 
*While symptom scores generally trended 
toward improvement, no statistically 
significant difference was found between 
the probiotic and placebo groups, 
indicating a strong placebo effect. 
Ruchkina et al 2013 60 1E7 CFUs B. 
longum and 
1E7 CFUs E. 




daily for 2 
weeks 
*Significant reduction in HBT scores 
compared to baseline (p < .01) in the 
treatment group.  
*Significant reduction in bacterial 
overgrowth syndrome in treatment group 
(p < .01) and 70.8% of participants 
experienced a return to eubiosis. 
Saltzman et al 1999 18 1E10 CFUs L. 
acidophilus 
BG2FO4 2x/d 




*No significant difference in HBT AUC 
from baseline values for either 
omeprazole or non-omeprazole group. 
*No significant differences in total or 
individual symptom scores from baseline 
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400mL of 2% 
unfermented 
milk containing 
any of 3 L. 
acidophilus 




*Significant reduction in HBT values 
observed in subjects taking L. acidophilus 
LA-1 milk at 1E8 CFUs/mL (p < .05) and 
S. thermophilus/L. bulgaricus milk at 1E8 
CFUs/mL (p < .05) as compared to 
control. 
* S. thermophilus/L. bulgaricus milk at 
1E8 CFUs/mL resulted in a greater 
reduction in symptoms than L. 
acidophilus milk of the same 
concentration. 


















*Total breath hydrogen excretion was 
reduced for milk containing lactose-grown 
B. longum (p = .0001) and milk 
containing B. longum ATCC (p = .0128) 
as compared to control.  
*Milk containing lactose-grown B. 
longum also resulted in lower hydrogen 
excretion than that of B. longum grown 





Table 2 (Continued)     
Research Team Year Sample Treatment(s) Findings 
Savaiano et al 1997 6 0.6g lactose/kg 
body wt/d, 
increasing to 
0.8g/kg day 3 
and 1g/kg day 
5, then 1g/kg/d 
was consumed 
until day 11 
*Fecal samples taken after lactose feeding 
showed appx 33% the rate of hydrogen 
gas production as fecal samples taken 
after the feeding of a dextrose control, and 
this difference was significant (p = .006). 








ending at 15g/d 
*Both mean and median HBT values 
consistently decreased with RP-G28 
treatment, but the difference was not 
significant. 
*Incidence of abdominal pain decreased 
significantly compared to placebo (p = 
.0288) and the number of subjects 
reporting no abdominal pain was 
significantly higher than placebo (p = 
.019). 
*Incidence of bloating and cramping was 
reduced as compared to baseline values in 
the treatment group, but not significantly 
more than placebo. 
Savaiano et al 2020 377 5g RP-G28 
galacto-
oligosaccharide 
2x/d for 10d 
increasing to 
7.5g 2x/d for 
20d, or 7.5g 
2x/d for 10d 
increasing to 
10g 2x/d for 
20d 
*There was a significantly greater 
incidence of reduction in total symptom 
scores with both the lower dose (p = .043) 
and the higher dose (p = .029) than the 
placebo. 
*In both treatment groups, there was a 
significantly greater likelihood of 
elimination of all GI symptoms (p = .004) 
than in the placebo group. 
*Treatment groups showed significantly 
higher milk consumption upon 30-day 
follow-up (p = .008) than placebo group. 
*Marked bifidogenic effect: Significant (p 
< .05) increases in relative abundance of 
Bifidobacterium longum, Bifidobacterium 
bifidum, Bifidobacterium breve, 
Bifidobacterium catenulatum, 
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*Significant reduction in AUC for 
hydrogen breath values in two separate 
trials (p = .0012 and p = .0156) as 
compared to placebo. 
*In one trial, significantly higher odds 
ratio of severe nausea was observed for 
probiotic as compared to the placebo (OR 
4.31) and lactase (6.98). 
*No significant reduction in incidence or 
severity of GI symptoms observed for 
probiotic treatment. 
Vitellio et al 2019 23 4E9 CFUs B. 
longum BB536 




B6 daily for 30 
days 
*Significant reduction in bloating noted in 
treatment group (p = .028) as compared to 
placebo.  
*87.5% of subjects initially experiencing 
constipation in treatment group achieved 
normal Bristol scores. 
*No statistically significant differences in 
abdominal pain between groups. 
*Significant increases (p < .05) in relative 
abundance of Slakia, Thricoccus, 
Bifidobacterium, and Enterococcus genera 
and significant decreases in Klesbiella, 
Serratia, and Enterobacter genera were 
observed in the treatment group as 
compared to placebo. 
Yesovitch et al 2004 10 VSL3 probiotic 
containing 
either 4.5E11 or 
1.8E12 CFUs of 






infantis, and S. 
salivarius daily 
for 17 days 
*No statistically significant reduction in 
HBT values nor symptom scores noted in 
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and appx 1E8 
CFUs B. 
animalis per 
gram 3x/d, as 
well as 2E8 
CFUs B. 
longum in 
capsule 3x/d for 
2 weeks 
*Beta-galactosidase activity in feces was 
significantly increased after treatment (p < 
.01), but not after 8-day follow-up. 
*Total symptom scores were significantly 




 Probiotics are live microorganisms that, when administered in sufficient amounts, promote 
health benefits. For the purpose of this review, synbiotic treatments that include a probiotic 
component are discussed in both this section and the synbiotics section. This allows for a more 
comprehensive assessment of the strength of evidence that a given probiotic species may affect 
outcomes of lactose intolerance.  
Bifidobacterium animalis 
 Bifidobacterium animalis describes Bifidobacterium animalis subspecies animalis and 
Bifidobacterium animalis subspecies lactis, once believed to be two separate species. It, like many of 
the bacterial species in this review, is a Gram-positive anaerobe. Though both subspecies have been 
studied for their probiotic properties, Bifidobacterium animalis subspecies lactis has been shown to 
grow easily in milk and milk-based media.101 
 Four studies in this review examined the effects of Bifidobacterium animalis on outcomes of 
lactose intolerance. Two studies showed a significant reduction in lactose intolerance symptom scores 





significant reduction in symptom scores were closely related and both featured a treatment of 
Bifidobacterium longum capsules combined with 125g yogurt containing Lactobacillus delbrueckii 
subspecies bulgaricus, Streptococcus thermophilus and Bifidobacterium animalis each day for 2 
weeks. Both research teams noted a Bifidogenic effect of the treatment and a significant reduction in 
the incidence of diarrhea as compared to the baseline values.76,79 In one study, the fecal beta-
galactosidase activity of participants was significantly increased following treatment.76 A 6-week 
study investigating the effect of Bifidobacterium animalis subspecies animalis IM386 combined with 
Lactobacillus plantarum MP2026 elucidated a significant reduction in the incidence of diarrhea and 
flatulence in both the probiotic and control groups as compared to baseline.77 This indicates a strong 
placebo effect. The researchers also did not find any significant differences in hydrogen breath test 
(HBT) values when compared to baseline values, and there was no correlation between HBT scores 
and symptoms. Effects of Bifidobacterium animalis subspecies lactis Bi-07 on lactose digestion were 
formally evaluated by the European Food Safety Authority based on the results of two unpublished 
studies provided by the health claim applicant. In these studies, the researchers noted significant 
reductions in HBT scores in the treatment group as compared to placebo, but no significant 
differences in attenuation of lactose intolerance symptoms.78 There was also a carryover effect 
observed between groups, so the results may have been marred by the adaptation of participants’ gut 
microbiomes to the probiotic treatment. The European Food Safety Authority ruled against the 
applicant’s health claim that the Bi-07 strain promoted a clear beneficial physiologic effect.78 
 Taken together, these findings provide little evidence that Bifidobacterium animalis 
supplementation is beneficial to individuals with lactose intolerance, and there may be strain-specific 
considerations when conducting research into the potential of either subspecies of this bacterium to 





effect of Bifidobacterium animalis combined with other probiotic species or prebiotic treatments, so it 
would be problematic to attribute the outcomes of those treatments to Bifidobacterium animalis alone. 
Bifidobacterium breve 
 Bifidobacterium breve is a bacterial species commonly used in probiotics for infants and in IBS 
research.102 Three studies in this review examined the effect of Bifidobacterium breve on outcomes of 
lactose intolerance. In 2012, the effect of a 4-week supplementation period of Lactobacillus casei 
Shirota and Bifidobacterium breve Yakult on lactose intolerance symptoms and hydrogen breath test 
values was investigated. The research team observed a significant reduction in both breath hydrogen 
and symptom scores compared to baseline values in the treatment group, and the reduction in total 
symptom scores was comparable to that observed for lactase enzyme.80 Upon 3-month follow-up, 
both lactose intolerance symptom scores and breath hydrogen scores remained significantly lower 
than baseline values, potentially indicating a lasting adaptation of the gut microbiome. A longer-term 
experiment investigated the effect of a 6-month regimen of the Bio-25 probiotic formula, which 
contains the following 11 bacteria: Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium 
longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, 
Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, and Streptococcus 
thermophilus. Each participant reported a reduction in baseline symptoms, but this was only 
statistically significant for bloating and flatulence, but not for diarrhea and abdominal pain.81 Two 
participants showed reduced HBT scores such that they were no longer diagnosed as lactose intolerant 
after only two months, whereas the other participants saw some non-significant reduction in breath 
hydrogen. Though the results of this study are promising, it was a pilot study and was limited by its 
small sample size of 8 subjects. Another pilot study measured hydrogen breath test values and 





Bifidobacterium breve, Bifidobacterium longum subspecies infantis, Bifidobacterium longum 
subspecies longum, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, 
Lactobacillus plantarum, and Streptococcus thermophilus. There were no significant reductions in 
lactose intolerance symptom scores nor HBT scores, though the study duration was fairly short for 
such a large (50g) lactose challenge.82 
 These studies provide a small degree of evidence that Bifidobacterium breve, when in 
combination with other probiotic species, may help attenuate outcomes of lactose intolerance. As with 
any study investigating a treatment that is comprised of multiple bacterial species, it is difficult to 
determine to what extent Bifidobacterium breve may have affected the outcome and to what extent it 
was facilitated by the other bacteria.   
Bifidobacterium bifidum 
 Bifidobacterium bifidum is a key microorganism in neonatal development, and its growth and 
prevalence in the gut microbiome are stimulated by human milk oligosaccharides early in life. It has 
the capacity to digest oligosaccharides found in mucin, which may allow this bacterium to more 
easily colonize the gastrointestinal tract.103 It has also been hypothesized that this digestion of 
intestinal mucin may promote increased mucin production by the host and contribute to the epithelial 
barrier of the intestines.104 
 Only one study included in this review investigated the effects of Bifidobacterium bifidum 
probiotic consumption on outcomes of lactose intolerance. The treatment was the aforementioned 6-
month regimen of the multi-probiotic Bio-25, which contains 11 probiotic species. While results 
trended toward a reduction in bloating and flatulence, and HBT scores were reduced, it would be 
unwise to attribute these effects solely to Bifidobacterium bifidum.81 This was also a pilot study with 





generalizable. Substantially more research is needed to determine the effectiveness of this bacterium 
at attenuating lactose intolerance outcomes. 
Bifidobacterium longum 
 Bifidobacterium longum is another Gram-positive, rod-shaped anaerobe colonizing the human GI 
tract, and taxonomically it is a combination of what were formerly three separate biotypes of 
Bifidobacteria: Bifidobacterium infantis, Bifidobacterium longum, and Bifidobacterium suis.105 It has 
the ability to digest a diverse range of carbohydrates in the intestines and is a common candidate for 
probiotic research.106 Bifidobacterium longum was present in 4 of the aforementioned studies included 
in this review. In combination with yogurt containing Bifidobacterium animalis and Lactobacillus 
delbrueckii subspecies bulgaricus, daily consumption of a probiotic capsule containing 
Bifidobacterium longum subspecies longum for 2 weeks was shown to alleviate diarrhea and promote 
a bifidogenic effect,76,79 and to increase fecal beta-galactosidase activity as compared to the control.76 
It was also present in the Bio-25 and VSL3 multi-probiotic treatments described previously,81,82 the 
former of which was associated with a reduction in lactose intolerance symptoms scores and a trend 
toward reduction in HBT values, while the latter showed no reduction in HBT values nor symptom 
scores.  
 Additionally, subjects receiving a 30-day treatment of 4E9 CFUs of Bifidobacterium longum 
subspecies longum BB536, 1E9 CFUs of Lactobacillus rhamnosus HN001, and 1.4mg vitamin B6 per 
day were observed to have significantly less bloating and a notable bifidogenic effect as compared to 
those receiving a maltodextrin and corn starch control.83 The researchers also observed a negative 
correlation between the relative abundance of Bifidobacterium in subjects’ feces and the outcomes of 
bloating and abdominal pain. Interestingly, the ability of Bifidobacterium longum to attenuate 





researchers recorded the effects on lactose intolerance outcomes of one-time consumption of 400mL 
lowfat milk either alone as a control, containing 5E8 CFUs/mL Bifidobacterium longum subspecies 
longum B6 grown using lactose, 5E8 CFUs/mL Bifidobacterium longum subspecies longum B6 
grown using both lactose and glucose, or 5E8 CFUs/mL Bifidobacterium longum subspecies longum 
ATCC 15708 grown using lactose. In this context, “B6” refers to the strain of bacterium, not vitamin 
B6 or pyridoxal as was the case in the previous study. Participants consuming the milk containing 
Bifidobacterium longum subspecies longum B6 that was grown using exclusively lactose experienced 
significantly less flatulence and lower HBT scores than the control group,84 and a reduction in HBT 
scores was also noted in the group consuming milk inoculated with Bifidobacterium longum 
subspecies longum ATCC 15708 grown with lactose. Lastly, researchers investigating the effects of 2 
weeks of daily supplementation with Bifidobacterium longum subspecies longum 107 and 
Enterococcus faecium 107 in patients with both severe lactase deficiency and dysbiosis discovered 
significant differences in the treatment group as compared to the control group. The treatment group 
showed both significantly lower HBT scores and a significantly greater percentage of subjects 
(70.8%) who were able to establish small bowel eubiosis by the end of the treatment period.85  
 Of the 7 studies in this review, 6 provided some evidence that Bifidobacterium longum, either 
alone or in combination with other probiotic species, may attenuate at least one outcome of lactose 
intolerance, while only one showed no significant results. Taken together, these studies provide strong 
evidence that Bifidobacterium longum probiotics may be a viable treatment option for lactose 
intolerance, but there is substantial heterogeneity in the taxa of Bifidobacterium longum that have 
been investigated, so it is as of yet unclear which subspecies or strain may be the best candidate for 







 Enterococcus faecium is a commensal bacterium that is potentially pathogenic if it over-
proliferates. It is a common cause of wound infections and urogenital infections, and it can be 
especially problematic if it develops vancomycin resistance. Enterococcus faecium is somewhat 
similar to Enterococcus faecalis, though the former can’t ferment mannitol.107 
 As described previously, a study investigating the effect of Bifidobacterium longum subspecies 
longum 107 and Enterococcus faecium 107 on HBT scores and re-establishment of eubiosis 
elucidated significant differences between the treatment group and control group85. It may be 
necessary to screen this bacterium for vancomycin resistance prior to its use as a probiotic agent, and 
there is still much room for research as to whether it is of any use in reducing undesirable outcomes of 
lactose intolerance.  
Lactobacillus acidophilus 
 Lactobacillus acidophilus is a Gram-positive microaerophilic bacterium that has been studied 
extensively for its probiotic properties. As early as 1977, it was demonstrated that Lactobacillus 
acidophilus NCFM inhibits the growth of pathogenic Clostridium perfringens, Salmonella enterica 
serovar Typhimurium (formerly Salmonella typhimurium), and Staphylococcus aureus, while 
Lactobacillus acidophilus 4962 inhibits the growth of Escherichia coli, Salmonella enterica serovar 
Typhimurium, and Staphylococcus aureus108. Yogurt is a common vehicle for administering 
Lactobacillus acidophilus as a probiotic, though care should be taken not to administer a hypercaloric 
diet because this has been associated with weight gain in subjects receiving yogurt-based 
Lactobacillus acidophilus treatment109. This is not always the case, however. Researchers may opt for 





durations of treatment vary greatly, each of which contributes to the diversity and heterogeneity of the 
available literature. 
 Of the 8 studies in this review that investigated the effects of Lactobacillus acidophilus, 2 have 
previously been described. The Bio-25 probiotic showed a reduction in lactose intolerance symptoms 
and a trend toward HBT score reduction81, while the VSL3 probiotic showed no significant reduction 
in either of these measures82. Of the 6 remaining studies, 5 showed some reduction in lactose 
intolerance symptoms or HBT scores associated with Lactobacillus acidophilus probiotic treatment, 
while one did not.  
 A crossover study investigating the effect of four treatments 400mL of milk combined with 
either Lactobacillus acidophilus B or Lactobacillus bulgaricus 449, each at concentrations of either 
1E8 CFUs/mL or 1E9 CFUs/mL, discovered a dose-dependent relationship. The one-time 
administration of Lactobacillus acidophilus milk containing 1E8 CFUs/mL failed to significantly 
reduce HBT scores or attenuate lactose intolerance symptoms, while milk with a concentration of 1E9 
CFUs was associated with a significant reduction in mean lactose intolerance symptom scores but not 
HBT scores.86 The subjects were allowed to consume black coffee during the treatment period, which 
has been shown to increase the survival rate of intestinal Lactobacillus acidophilus and, particularly 
in the case of dark roast coffee, may inhibit the growth of Escherichia coli and Staphylococcus 
aureus.110 In another crossover study, supplementation of 1E10 CFUs of Lactobacillus acidophilus 
for 4 weeks in a maltodextrin capsule was shown to significantly reduce diarrhea, abdominal 
cramping, vomiting, and mean symptom scores upon 25g lactose challenge as compared to the 
control, although flatulence scores were somewhat elevated at the end of the treatment period.87 There 





 In a study of 20 children with lactose maldigestion, subjects received 250mL of milk containing 
a total dose of 1E10 CFUs Lactobacillus acidophilus NCFM, the same volume of milk containing 
1E10 CFUs Streptococcus thermophilus and 1E8 CFUs Lactobacillus delbrueckii subspecies lactis, 
and 250mL of an uninoculated control milk, each one day apart. Only 8 subjects were able to 
consume the required amount of each treatment, so these were the only subjects included in the final 
analysis. Despite this, mean symptom scores were significantly lower upon consumption of the 
Lactobacillus acidophilus milk than the control, while HBT scores were somewhat, but not 
significantly, higher.88 In addition to poor rates of completion of the treatment by participants, this 
study was limited by the exceptionally short washout period between treatments, such that there is a 
high risk of a carryover effect. 
 Another study of the effect of milks inoculated with Lactobacillus acidophilus on HBT scores 
revealed a reduction for 2 of the 3 doses tested. Subjects were fed 10mL/kg body weight per day of 
either an uninoculated control milk or milk inoculated with 1E6 CFUs/mL, 1E7 CFUs/mL, or 1E8 
CFUs/mL Lactobacillus acidophilus for one week. For subjects of a typical weight, this would 
amount to several servings of milk per day. The subjects consuming milk containing 1E6 and 1E8 
CFUs of Lactobacillus acidophilus had significantly lower HBT scores than the control, but this 
effect was not observed for the dose of 1E7 CFUs/mL.89 The researchers did not detect any significant 
differences in lactose intolerance symptom scores, and the study was also limited by the small sample 
size of 6 subjects in each group. 
 Similarly, subjects receiving 2E10 CFUs of Lactobacillus acidophilus BG2FO4 for one week 
were observed to have no significant reduction in individual or total symptom scores, and the 





Interestingly, participants in this study self-reported their lactose intolerance, but approximately half 
of the subjects were found to be lactose digesters.  
 Finally, a study investigating the effect of milks inoculated with 2 different doses of 3 strains of 
Lactobacillus acidophilus and of yogurt starter culture revealed a strain-dependent effect on HBT 
scores. Subjects received 400mL of milk containing Lactobacillus acidophilus LA-1, Lactobacillus 
acidophilus LA-2, Lactobacillus acidophilus NCFM, or both Streptococcus thermophilus and 
Lactobacillus delbrueckii subspecies bulgaricus, and each probiotic treatment was administered in 
concentrations of either 1E7 or 1E8 CFUs/mL. Significant reductions in HBT scores were observed 
for milk containing 1E8 CFUs/mL of Lactobacillus acidophilus and milk containing the same 
concentrations of Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus.91 
There was also a reduction in overall symptom scores in the latter group.  
 There is a moderate degree of evidence that some strains and doses of Lactobacillus acidophilus 
may reduce undesirable outcomes of lactose intolerance. Of the 8 studies in this review, 6 showed a 
significant reduction in either HBT scores or lactose intolerance symptoms, and 5 showed a 
significant reduction in symptoms. Common limitations of these studies included short washout 
periods between trials and small sample sizes. Future research could benefit from more homogeneity 
in study duration, strain selection, and dosage to determine the most effective treatment modality. 
Lactobacillus delbrueckii subspecies bulgaricus 
 Lactobacillus delbrueckii subspecies bulgaricus is, like many of the bacteria in this review, a 
Gram-positive, non-motile, non-spore forming bacterium. It is commonly used in the production of 
fermented dairy products, particularly yogurt,111 and this use of Lactobacillus delbrueckii was briefly 
featured in episode 6 of the animated science fiction series Love, Death, and Robots.112 Qualities of 





galactosidase producing gene and its inability to digest the galactose monosaccharide upon the 
cleavage of lactose.113 Rather than digesting galactose, Lactobacillus delbrueckii subspecies 
bulgaricus releases it into its external environment. This is nutritionally relevant in that galactose 
exuded into the small intestine by probiotic bacteria may be absorbed by the host and thus may 
potentially reduce bacterial gas production. 
 Of the 6 studies examining the effects of Lactobacillus delbrueckii subspecies bulgaricus on 
outcomes of lactose intolerance, 5 have previously been described. Daily consumption of a probiotic 
capsule containing Bifidobacterium longum subspecies longum for 2 weeks along with 125g yogurt 
fermented using Lactobacillus delbrueckii subspecies bulgaricus and fortified with Bifidobacterium 
animalis was shown to alleviate diarrhea and promote a bifidogenic effect,76,79 and to increase fecal 
beta-galactosidase activity as compared to the control.76 By contrast, a 17-day study investigating the 
effect of the VSL3 multi-probiotic containing Lactobacillus delbrueckii subspecies bulgaricus 
discovered no significant difference in HBT scores nor symptom scores as compared to baseline,82 
though the 50g lactose challenge may have been a limitation. A single dose of nonfermented milk 
containing either 1E8 or 1E9 CFUs of this probiotic bacterium significantly reduced both HBT scores 
and total symptom scores as compared to baseline at either bacterial concentration.86 This research 
team also noted a moderate degree of bile sensitivity and ease of cell wall lysis in Lactobacillus 
delbrueckii subspecies bulgaricus, which likely contributes to host lactose digestion via the release of 
endogenously-produced bacterial lactase upon lysis. This contextualizes the increase in fecal beta-
galactosidase observed in a previous study.76 Also, one-time consumption of 400mL of milk 
containing Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus in 
concentrations of either 1E7 or 1E8 CFUs/mL was shown to reduce both incidence of lactose 





lactase enzyme concentration (3 standard units/mL) in the milk inoculated with Lactobacillus 
delbrueckii subspecies bulgaricus prior to its consumption. Another yogurt study investigated the 
effect of consumption of 500g/day for 15 days of either unpasteurized yogurt containing greater than 
or equal to 1E7 CFUs of Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus 
thermophilus or pasteurized but otherwise identical yogurt. Outcomes measured included blood 
glucose, serum lipids, serum short-chain fatty acids, and HBT scores. In lactose maldigesters, HBT 
scores were significantly lower, both initially and also after 15 days of fresh yogurt consumption, as 
compared to baseline values, but this effect was not observed for pasteurized yogurt.92 Lactose-
intolerant subjects also had significantly higher plasma propionate concentrations after the treatment 
period than at baseline, but no other findings were significant for this group. 
 Taken together, these studies provide moderately strong evidence that Lactobacillus delbrueckii 
subspecies bulgaricus probiotics, particularly as a component of either yogurt or probiotic-fortified 
dairy products, may be effective at reducing deleterious outcomes of lactose intolerance. In future 
research, follow-up symptom score assessments may be useful to determine if these effects persist 
beyond the 8-hour window for which outcomes were commonly recorded in the above studies. Due to 
its high degree of beta-galactosidase production and activity and its tendency to exude rather than 
ferment galactose, this bacterium is an interesting and promising candidate for potential probiotic 
treatment of lactose intolerance.  
Lactobacillus casei 
 Lactobacillus casei is a probiotic bacterium that is closely related to Lactobacillus paracasei and 
Lactobacillus rhamnosus. It has been studied extensively for its probiotic potential, and it has been 
shown to have a high degree of acid-resistance and potential bile salt resistance,114 which may help 





 Studies investigating the effects of Lactobacillus casei by itself are rare, as it’s commonly 
included in multi-probiotic treatments. In the aforementioned study investigating the effect of daily 
consumption of a probiotic containing Lactobacillus casei Shirota and Bifidobacterium breve Yakult 
for 4 weeks, the treatment resulted in a reduction in baseline lactose intolerance symptom scores and 
HBT values upon completion of the treatment regimen, and these effects persisted in a 3-month 
follow-up.80 The Bio-25 pilot study also showed a significant reduction in lactose intolerance 
symptom scores after a 6-month treatment with a multi-probiotic containing Lactobacillus casei.81 By 
contrast, subjects consuming the VSL3 multi-probiotic containing Lactobacillus casei were not 
observed to have any reduction in symptom scores nor HBT values.82  
 There is a small degree of evidence that Lactobacillus casei may, when combined with other 
probiotics, have some effect on outcomes of lactose intolerance, but more research is needed. In 
particular, research that investigates the effect of solely Lactobacillus casei on these outcomes in 
lactose intolerant individuals would contribute greatly to the literature. 
Lactobacillus helveticus 
 Lactobacillus helveticus is a potentially probiotic bacterium that is closely related to 
Lactobacillus acidophilus. While it has not, as of yet, been as extensively researched as many other 
probiotics, it has been shown to adhere well to the host’s mucosal layer and to competitively exclude 
the pathogenic bacteria Escherichia coli 0157:H7 and Campylobacter jejuni.115 Only one study93 in 
this review investigated the effects of Lactobacillus helveticus on outcomes of lactose intolerance in 
lactose maldigesters, and its results are not especially generalizable to a larger population. A 2010 
study investigated the effects of daily consumption of 4E9 CFUs of Lactobacillus rhamnosus Rosell-
11 and Lactobacillus helveticus Rosell-52 for 2 weeks on symptom scores and HBT values in children 





researchers noted a significant decrease in HBT scores and the number of asymptomatic subjects, the 
latter of which improved from 13.9% of subjects at baseline to 58.2% of subjects following treatment 
of the live probiotic.93 As with Lactobacillus casei, it would be useful to investigate the effect of 
Lactobacillus helveticus alone rather than in combination with another probiotic species, and this 
study population is not representative of typical lactose maldigesters, so there is not sufficient 
evidence to determine the effect of Lactobacillus helveticus on outcomes of lactose intolerance in 
typical lactose-intolerant individuals. 
Lactobacillus delbrueckii subspecies lactis 
 Lactobacillus delbrueckii subspecies lactis is similar to Lactobacillus delbrueckii subspecies 
bulgaricus in that it’s commonly used in the production of fermented dairy products, especially 
yogurt. In the literature, this bacterium should be clearly differentiated from Lactococcus lactis, as 
Lactobacillus delbrueckii subspecies lactis was formerly considered the separate species 
Lactobacillus lactis, thus “L. lactis” is somewhat ambiguous. In contrast to the bulgaricus subspecies, 
the lactis subspecies has retained more ancestral genes pertaining to carbohydrate digestion, and it is 
specialized toward absorbing lactose via a phosphotransferase system that excels in lower 
concentrations of lactose than the bulgaricus subspecies.113 Despite this method of lactose transport, it 
may prove to be a similarly effective probiotic in attenuating undesirable lactose intolerance 
outcomes. 
 This bacterium was present in the Bio-25 probiotic, which has shown some ability to alleviate 
lactose intolerance symptoms when taken daily for 6 months,81 and Lactobacillus delbrueckii 
subspecies bulgaricus was also used, as part of a yogurt starter culture, to inoculate milk that was 
administered to lactose-maldigesting children in 250mL doses. Researchers in the latter study 





baseline in the lactose-maldigesting children who completed the treatment,88 but full compliance was 
only achieved by 8 of 20 children. While results were generally positive for both treatments, these 
studies do not provide strong evidence that Lactobacillus delbrueckii subspecies lactis has a reliable 
effect on outcomes of lactose intolerance, and more research is needed. It may be useful to include the 
bacterium as a component of yogurt or inoculated milk, as is often done with the bulgaricus 
subspecies. 
Lactobacillus paracasei 
 Lactobacillus paracasei is, as the name may imply, closely related to Lactobacillus casei, so 
much so that they share many of the same properties and have historically been difficult to 
differentiate from one another. Like its relatives, this bacterium is commonly used to ferment dairy 
products and is a viable probiotic candidate due to its acid resistance and inhibition of the 
proliferation of Helicobacter pylori.114 In this review, only the Bio-25 multi-probiotic study 
investigated a treatment containing Lactobacillus paracasei,81 so there is little evidence to support its 
use as a probiotic to attenuate lactose intolerance outcomes.  
Lactobacillus plantarum 
 Lactobacillus plantarum is a Gram-positive, genetically diverse, aerotolerant bacterium 
commonly found in animal products and fermented vegetable foods such as kimchi.116 Due to its 
ability to digest lactose and its acid tolerance, it is a candidate bacterium for the digestion of silage 
and waste products such as whey that are produced in dairy manufacturing.117 These qualities also 
make Lactobacillus plantarum a suitable candidate for lactose intolerance research. 
 Several studies described above included Lactobacillus plantarum as part of a multi-probiotic 
treatment, including the Bio-25 pilot study81 and VSL3 pilot study.82 Additionally, daily consumption 





Lactobacillus plantarum MP2026 resulted in significant reduction in the incidence of diarrhea and 
flatulence compared to baseline, but no other symptoms, and HBT scores were unaffected.77 In a 2020 
randomized controlled trial, the daily consumption of 3E9 CFUs of Pedicoccus acidilactici and 
Lactobacillus plantarum strains CECT7484 and CECT7485 for 8 weeks was associated with a 
significant reduction in total symptom incidence and severity scores in the treatment group.94 Nearly 
half (46.4%) of the treatment group experienced greater than or equal to 50% reduction in symptoms, 
while none of the control group experienced this.  
 Together, these studies provide a moderately low degree of evidence that Lactobacillus 
plantarum, in combination with other probiotic bacteria, may attenuate undesirable lactose intolerance 
outcomes. More research is needed, but this bacterium is a promising candidate for probiotic 
interventions in lactose intolerant populations.  
Lactobacillus reuteri 
 Lactobacillus reuteri is a commensal bacterium normally present in the human gut that has been 
shown to produce antimicrobial peptides and perform competitive exclusion of pathogenic bacteria. It 
is adapted to a wide range of conditions and hosts, and it colonizes the proximal GI tract as well as the 
colon,118 which sets it apart from many other probiotic bacteria and makes it a promising research 
candidate. A 2010 study involving 60 lactose intolerant patients investigated the effects of either 9000 
units of lactase enzyme immediately before a lactose challenge or daily consumption of 8E8 CFUs of 
Lactobacillus reuteri in pill form 10 days before a lactose challenge. Both treatment groups 
experienced statistically significant reductions in total symptom scores, each individual symptom 
score, and HBT scores.95 The group receiving lactase enzyme showed significantly lower scores than 
the probiotic group, so more research is needed to determine whether Lactobacillus reuteri potentially 






 As mentioned above, Lactobacillus rhamnosus is genetically and functionally similar to both 
Lactobacillus casei and Lactobacillus paracasei. One characteristic that makes Lactobacillus 
rhamnosus an interesting probiotic candidate is the presence of mucous-binding proteins on the tips of 
its pili.37 This bacterium, particularly the GG strain, is commonly used in food manufacturing and has 
been studied for its probiotic potential,119 but the interventions included in this review either do not 
specify a strain or involve non-GG strains.  
 The Bio-25 multi-probiotic, which again was associated with some significant symptom 
reduction, contained Lactobacillus rhamnosus.81 A synbiotic study investigated the effect of 4E9 
CFUs of Bifidobacterium longum subspecies longum BB536, 1E9 CFUs of Lactobacillus rhamnosus 
HN001, and 1.4mg vitamin B6 per day on lactose intolerance symptoms and gut microbiome 
composition. The researchers observed a negative correlation between the relative abundance of 
Bifidobacterium in subjects’ feces and the outcomes of bloating and abdominal pain, a significant 
reduction in bloating and constipation, and significant decreases in Klesbiella, Serratia, and 
Enterobacter genera in the treatment group.83 Also, as discussed above, daily consumption of 4E9 
CFUs of Lactobacillus rhamnosus Rosell-11 and Lactobacillus helveticus Rosell-52 in children from 
10 to 12 years of age was associated with a significant decrease in HBT scores and in the number of 
asymptomatic subjects.93 
 Taken together, these studies provide a small degree of evidence that Lactobacillus rhamnosus 
probiotics, when in combination with other probiotic species, may attenuate undesirable outcomes of 
lactose intolerance. Further research will be necessary to determine which strains and what dosages 
are the most effective. It may also be useful to see Lactobacillus rhamnosus studied alone rather than 






 Pediococcus acidilactici is a Gram-positive, sphere-shaped, comparatively resilient bacterium 
that colonizes the entire human gastrointestinal tract. This makes it a promising probiotic candidate, 
and it has been studied for the potential anti-tumor, immunomodulatory, and antioxidant properties of 
its metabolites.120 There is little evidence that Pediococcus acidilactici has an effect on outcomes of 
lactose intolerance, however. As mentioned above, an 8-week study investigated the effects of daily 
supplementation of Pediococcus acidilactici CECT7483 and Lactobacillus plantarum strains 
CECT7484 and CECT7485 on outcomes of lactose intolerance and found a significant reduction in 
total symptom scores and symptom severity in the treatment group,94 but substantially more research 
is needed to determine to what extent this effect was promoted by Pediococcus acidilactici 
specifically. 
Streptococcus thermophilus 
 Streptococcus thermophilus is another Gram-positive, non-spore forming, non-motile anaerobe, 
and it is used alongside Lactobacillus delbrueckii subspecies bulgaricus to ferment dairy products. 
The two species are mutualistic as they supply one another with amino acids, formic acid, folic acid, 
and carbon dioxide for essential metabolic processes.121 It has been studied extensively for its 
probiotic properties and for its production of metabolically useful metabolites, including the ability of 
the APC151 strain to produce GABA in yogurt.122  
 As it is commonly found alongside other bacteria, it may be difficult to separate the beneficial 
effects of Streptococcus thermophilus from the effects of other probiotics commonly included in 
yogurt or fortified into probiotic milks. Consequently, each Streptococcus thermophilus study 
included in this review has been described above. Daily consumption of 125g yogurt containing 





bulgaricus alongside a probiotic capsule containing Bifidobacterium longum subspecies longum for 2 
weeks was associated with a reduction in diarrhea, promotion of a bifidogenic effect,76,79 and an 
increase in fecal beta-galactosidase activity.76 The Bio-25 multi-probiotic included Streptococcus 
thermophilus and was associated with alleviation of some lactose intolerance symptoms.81 Children 
with lactose maldigestion who were given 400mL of milk inoculated with 10E8 CFUs Lactobacillus 
delbrueckii subspecies lactis and 1E11 CFUs Streptococcus thermophilus showed significant 
reductions in total symptom scores and HBT values compared to baseline, although compliance was 
poor (40%) for this subgroup.88 A dose-dependent relationship may also exist for this bacterium. A 
study investigating the effects of one-time consumption of 400mL of milk inoculated with 1E7 
CFUs/mL or 1E8 CFUs/mL of a yogurt starter culture or of various strains of Lactobacillus 
acidophilus concluded that higher doses (1E8 CFUs/mL) of the yogurt starter culture containing 
Streptococcus thermophilus and Lactobacillus delbrueckii subspecies lactis effectively reduced 
lactose intolerance symptoms and HBT values.91 Also, fresh yogurt containing Streptococcus 
thermophilus and Lactobacillus delbrueckii subspecies bulgaricus was shown to reduce HBT scores 
more than pasteurized yogurt.92 
 All 6 studies investigating the effects of Streptococcus thermophilus probiotics, yogurts, or 
inoculated milks found significant reductions in at least one outcome of lactose intolerance. This 
bacterium shows a strong degree of evidence for attenuation of undesirable lactose intolerance 
outcomes, with caveat that this effect may be due to any of the other bacteria in the multi-probiotic 
treatments that were administered. This is not necessarily problematic, as studying Streptococcus 
thermophilus alone, as an axenic probiotic, might remove the mutualistic benefit offered by 







 Prebiotics, as a reminder, are substrates that are selectively utilized by the host’s microbes to 
confer a health benefit upon the host, in this context by promoting adaptive changes in the 
composition of the gut microbiome.9 These are commonly indigestible carbohydrates, or even poorly-
digested carbohydrates such as raffinose and stachyose. In the case of lactose intolerant individuals, 
lactose is an indigestible or poorly-digested carbohydrate, so it potentially fits the definition of a 
prebiotic, and studies investigating the prebiotic potential of lactose were included in this review. 
Studies that investigated the effects of bacterial inoculations, supplementation, or fortification in 
combination with lactose or lactose-containing foods were considered synbiotic rather than prebiotic 
studies for the purpose of this review. This includes studies in which yogurt was the treatment. 
Lactose  
 There are logistical and potentially even ethical issues with using lactose as a treatment in 
lactose-intolerant individuals. Researchers should be mindful of the discomfort, pain, and undesirable 
outcomes that will likely be experienced by subjects when this treatment is applied, and substantial 
attrition should be expected. Two studies included in this review investigated the effect of either 
lactose or milk administered to lactose-intolerant subjects. The first investigated the effect of 
increasing doses of lactose on hydrogen gas production and consumption over 10 days. The initial 
dose was 0.6g/kg body weight on day 1, which increased to 0.8g/kg day 3 and 1g/kg day 5, which is 
equivalent to more than 4 glasses of milk for most subjects. Interestingly, fecal hydrogen production 
by each fecal bolus was measured for 24 hours after defecation, and fecal hydrogen production was 
significantly lower in the lactose group at 3 hours and 24 hours.96 No breath hydrogen scores were 
recorded, nor were symptom scores, but this study does provide some evidence of potential microbial 





 The second study investigated the effect of raw milk consumption, as compared to pasteurized 
milk or soy milk consumption, on breath hydrogen production and lactose intolerance symptom 
scores. In a crossover trial, subjects consumed raw milk in doses that began at 16 ounces on day 1, 
dropped to 4 ounces on day 2, increased by 4 ounces per day until day 7, then returned to a baseline 
dose of 16 ounces on day 8. Hydrogen breath tests were performed in response to the 16-ounce bolus 
of milk on days 1 and 8. There was a borderline significant reduction in total and peak hydrogen gas 
production by subjects consuming raw milk,97 and these values were comparable to those observed 
for consumption of pasteurized milk on day 8. This may indicate some colonic microbial adaptation 
to raw milk, but not in excess of that observed for pasteurized milk. No differences in symptom scores 
were observed. No evidence was found to support the use of lactose as a prebiotic to attenuate 
undesirable outcomes of lactose intolerance. 
RP-G28 galacto-oligosaccharide 
 Two studies included in this review investigated the effect of a novel glacto-oligosaccharide on 
outcomes of lactose intolerance. The first investigated the effects of two levels of RP-G28 galacto-
oligosaccharide on symptom scores, number of responders (those with a reduction in symptom 
composite score of 4 or greater or those reporting a symptom score of 0), quality of life, gut 
microbiome composition, and lactose consumption upon follow-up. In total, 377 subjects were 
included and randomized into three groups. One received a corn starch based placebo, one received 
5g of the treatment 2 times per day for 10 days then 7.5g of the treatment 2 times per day for 20 days, 
and the third group received 7.5g of the treatment 2 times per day for 10 days then 10g of the 
treatment 2 times per day for 20 days. There was a 40% response rate to RP-28 treatment and a 26% 
response rate to the placebo, and there were significant reductions in abdominal pain, abdominal 





each treatment group also reported consuming significantly more milk per day than they had 
previously, and this increase was greater than that seen in the placebo group, potentially indicating an 
increase in milk tolerability.98 
 The second study investigated the effects of the same prebiotic in escalating doses of 1.5g/day to 
a maximum of 15g/day over the course of 35 days on HBT scores and lactose intolerance symptoms. 
Self-reported dairy consumption and an additional HBT were recorded during a 30-day follow-up. 
Compared to the corn syrup placebo, subjects consuming the prebiotic experienced generally, but not 
significantly, lower HBT scores.99 Lactose intolerance symptom scores trended toward reduction, 
with 72% of the treatment group reporting a reduction in symptoms as compared to 28% of the 
placebo group. The number of subjects reporting no abdominal pain by the end of the treatment 
period was significantly higher for the treatment group than the placebo group. Subjects in the 
treatment group were also significantly more likely to report tolerance of dairy upon follow-up. 
Symptom scores, interestingly, were lower upon follow-up than they were at the end of the treatment 
period.99 Taken together, these findings indicate some promise for RP-G28’s potential to alleviate 
deleterious outcomes of lactose intolerance. Of note is that there was a substantial overlap in the 
membership of the research teams conducting these two studies. In the interest of replication, it would 
be helpful to see a similar study conducted by an unrelated research team.  
Synbiotics 
 Synbiotics are mixtures of probiotics and substrates selectively utilized by those probiotics that 
confer a health benefit upon the host. For the purpose of this review, yogurt was considered a 
synbiotic treatment, as was the treatment composed of Bifidobacterium longum subspecies longum, 
Lactobacillus rhamnosus, and vitamin B6. Although, strictly speaking, vitamin B6 is ostensibly not 





generally involves any bacterium combined with a micronutrient or macronutrient intended to support 
the probiotic potential of the bacterium, so a more inclusive interpretation of synbiotics will be 
applied in this case. 
Inoculated dairy products 
 Inoculated dairy products contain both lactose-hydrolyzing bacteria as well as the nutrient-rich 
media in which these bacteria might propagate, both prior to digestion and when they are introduced 
to the bacterial milieu of the gastrointestinal tract. In total, 9 studies included in this systematic review 
investigated the effect of inoculated dairy products on outcomes of lactose intolerance. Within these 
studies, treatments that were associated with reductions in both symptom scores and HBT values were 
400mL of milk inoculated with 5E8 CFUs/mL of lactose-fed Bifidobacterium longum B6,84 400mL of 
milk inoculated with 1E8 or 1E9 CFUs/mL of Lactobacillus delbrueckii subspecies bulgaricus,86 
250mL of milk inoculated with 1E8 CFUs/mL Lactobacillus delbrueckii subspecies lactis and 1E10 
CFUs/mL Streptococcus thermophilus administered to children with lactose intolerance,88 and 400mL 
of milk inoculated with 1E8 CFUs/mL of Lactobacillus delbrueckii subspecies bulgaricus and 
Streptococcus thermophilus.91 Treatments that were associated with symptom score reduction but not 
HBT score reduction were 125g yogurt containing Lactobacillus delbrueckii subspecies bulgaricus, 
Streptococcus thermophilus and Bifidobacterium animalis combined with a probiotic capsule 
containing 2E8 CFUs of Bifidobacterium longum,76,79 as well as a treatment of 25g of lactose from an 
unspecified quantity of unpasteurized yogurt containing 1E8 CFUs/g Lactobacillus delbrueckii 
subspecies bulgaricus and Streptococcus thermophilus.100 Treatments associated with a reduction in 
HBT scores but not symptom scores were 500g/day fresh yogurt containing greater than or equal to 
1E7 CFUs/g of Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus,92 as 





acidophilus.89 Taken together, these studies provide moderately strong evidence that inoculated dairy 
products containing at least 1E8 CFUs/mL of Lactobacillus delbrueckii, particularly subspecies 
bulgaricus, and Streptococcus thermophilus may attenuate undesirable outcomes of lactose 
intolerance.  
Probiotics combined with vitamin B6 
 One synbiotic study included in this review investigated the effects of 4E9 CFUs of 
Bifidobacterium longum subspecies longum BB536, 1E9 CFUs of Lactobacillus rhamnosus HN001, 
and 1.4mg vitamin B6 per day on outcomes of lactose intolerance, including symptom scores and gut 
microbiome composition. The treatment was associated with a notable Bifidogenic effect and 
significantly less bloating as compared to the control.83 This study does not provide conclusive 
evidence that vitamin B6 has a synergistic effect on Bifidobacterium longum and Lactobacillus 









 In this systematic review of 25 studies investigating the effects of probiotic, prebiotic, and 
synbiotic interventions on outcomes of lactose intolerance, there was a generally positive effect of 
nearly all treatments. Only 2 probiotic studies and 2 milk/lactose prebiotic studies showed a complete 
lack of significant improvement in any of the outcomes assessed for each included study. One of these 
probiotic studies utilized a large bolus of 50g lactose for the lactose challenge after a relatively short 
treatment duration,82 and half of the participants in the other probiotic study were found to be lactose 
digesters upon closer examination,90 so the lack of significant differences may be explained by the 
methodology employed in these studies. Moderately strong evidence for attenuation of lactose 
intolerance outcomes was observed for Bifidobacterium longum, Lactobacillus delbrueckii subspecies 
bulgaricus, Lactobacillus acidophilus, and Streptococcus thermophilus. A 2018 systematic review 
assessing the same outcomes from among 15 probiotic and prebiotic studies also concluded that 
Bifidobacterium longum probiotic supplementation showed a moderately strong degree of evidence of 
its effectiveness,70 and a similar conclusion was reached in a 9-study 2020 systematic review,71 so this 
bacterium may be an especially promising candidate for future lactose intolerance research.  
 The beneficial effects of the ingestion of lactic acid bacteria used as yogurt starter cultures, e.g. 
Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus, are likely due to the 
lysis of bacterial cells in the consumer’s stomach and the release of bacterial beta-galactosidase. This 
is noteworthy because traditional probiotic benefits are often presumed to come from bacterial 
colonization. Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus do not 
generally survive passage through the digestive tract, particularly if the product containing the 
bacteria is heat-treated.123 Lysis of these bacteria in the stomach and failure to colonize the 





fruitful to investigate the duration of improvement of lactose intolerance outcomes upon ingestion of 
inoculated dairy products as compared to ingestion of lactase enzyme pills or capsules. 
Bifidobacterium longum probiotics, by contrast, may have a longer-term effect on lactose 
maldigestion due to the ability of probiotic capsules to remain intact in the stomach and release their 
contents in the intestine.124 In either case, further research is necessary to determine the duration of 
the beneficial effects of these probiotic bacteria and the precise mechanisms of action that promote 
the observed benefits. 
  Although a meta-analysis was originally planned, the substantial methodological heterogeneity 
between studies included in this review prevented pooling or statistical comparison of results. Studies 
varied in treatment dosage, method or schedule of treatment administration, dietary restriction 
imposed upon subjects, contents of multi-probiotics administered, duration, follow-up protocols, mass 
of the lactose bolus used for the HBT, and scale used to measure or report lactose intolerance 
symptom scores. Future studies may benefit from consistency, or even homogeneity, in these 
parameters, though few validated methods and agreed-upon values exist for each. The quantity of 
lactose for assessing HBT scores is a minor exception. Formerly, this test used a 50g bolus but has 
shown approximately equal sensitivity with a 25g bolus of lactose125 and researchers are beginning to 
recognize the problematic nature of assessing lactose intolerance using a full 50g bolus of an 
indigestible carbohydrate.126 It may be more practically useful to simply assess lactose intolerance 
symptoms, as HBT scores are not always closely associated with lactose intolerance symptom scores.  
 Gut microbiome composition may be a fruitful treatment outcome to investigate. Some studies 
noted a Bifidogenic effect of probiotic treatment and a reduction in lactose intolerance symptom 
scores, so it may be useful to assess how long this colonic adaptation persists via a follow-up 





colonization, and long-term attenuation of undesirable lactose intolerance outcomes. The duration for 
which a probiotic treatment persists will depend on the resilience of the microbiota. In microbiome 
research, resilience is the ability of the microbiome to return to its baseline composition following a 
perturbation or alteration.127 Such alterations may be caused by foodborne illness, dietary changes, a 
regimen of antibiotics, a regimen of probiotics, or other factors. In the context of a probiotic regimen, 
maintaining a diet that selectively supports the probiotic bacteria could favorably reduce resilience 
and lengthen the duration of treatment.128  
 Another noteworthy consideration is the safety of probiotic treatments. Each probiotic bacterium 
may have its own considerations or risks. As mentioned above, Enterococcus faecium is potentially 
pathogenic, so it should not be taken as a probiotic by those with any significant immunosuppression, 
nor if the strain is found to have vancomycin resistance.107 Otherwise, no overtly pathogenic bacteria 
are known to be common probiotics. In a study129 investigating the effect of a multispecies probiotic 2 
times per day for 4 weeks on fecal and gastrointestinal outcomes of 298 patients with severe acute 
pancreatitis, 9 subjects within the treatment group (n = 153) developed bowel ischemia and 8 of these 
subjects died. The researchers offered the hypothesis that the probiotic treatment may have increased 
local intestinal oxygen demand and promoted bowel ischemia,129 so risk of bowel ischemia may be a 
contraindication of probiotics in the acute care setting. Other sensible contraindications may include 
the presence or history of bowel perforation, which risks bacterial translocation into the host’s 
systemic circulation. Otherwise, probiotics that are applied to food, in addition to a variety of 









 A systematic review of 25 studies revealed a moderately strong degree of evidence that 
Bifidobacterium longum, Lactobacillus delbrueckii subspecies bulgaricus, and Streptococcus 
thermophilus probiotics can alleviate undesirable outcomes of lactose intolerance. There was strong 
evidence that inoculated dairy products containing Lactobacillus acidophilus, Lactobacillus 
delbrueckii subspecies bulgaricus, and/or Streptococcus thermophilus can also alleviate undesirable 
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